CF PHARMTECH (02652) Surges Over 21% in Intraday Trading as Advanced Respiratory Pipeline Accelerates Towards Harvest Phase

Stock News03-18 10:14

CF PHARMTECH (02652) saw its shares rise more than 21% during the morning session. At the time of writing, the stock was up 14.54%, trading at HK$28.2, with a turnover of HK$81.96 million. The surge follows recent news that the company's self-developed inhaled powder ICF001, a改良型新药 (chemical drug category 2.1改良型新药) for treating pulmonary arterial hypertension (PAH) and interstitial lung disease-associated pulmonary arterial hypertension (PH-ILD), has had its Investigational New Drug (IND) application formally accepted by China's National Medical Products Administration (NMPA). This marks the company's second吸入制剂改良型创新药 to receive acceptance, following ICF004, signaling that its innovative pipeline in advanced respiratory formulations is accelerating into a harvest period. Starting March 9, CF PHARMTECH was officially included in the Hong Kong Stock Connect list of eligible securities. The board anticipates that this inclusion will help broaden the company's shareholder base and enhance the trading liquidity of its H-shares. A recent research report from Huaxin Securities noted that the company continues to focus on innovation, with its new PAH treatment drug expected to file an IND application within the year. Considering the sequential clinical application submissions of the company's globally patented innovative drugs, Huaxin Securities has assigned a "Buy" investment rating.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1105666137?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-18 10:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1105666137","market":"us","top_or_hot":-1,"title":"CF PHARMTECH (02652) Surges Over 21% in Intraday Trading as Advanced Respiratory Pipeline Accelerates Towards Harvest Phase","media":"Stock News","content":"<p>CF PHARMTECH (02652) saw its shares rise more than 21% during the morning session. At the time of writing, the stock was up 14.54%, trading at HK$28.2, with a turnover of HK$81.96 million. The surge follows recent news that the company's self-developed inhaled powder ICF001, a改良型新药 (chemical drug category 2.1改良型新药) for treating pulmonary arterial hypertension (PAH) and interstitial lung disease-associated pulmonary arterial hypertension (PH-ILD), has had its Investigational New Drug (IND) application formally accepted by China's National Medical Products Administration (NMPA). This marks the company's second吸入制剂改良型创新药 to receive acceptance, following ICF004, signaling that its innovative pipeline in advanced respiratory formulations is accelerating into a harvest period. Starting March 9, CF PHARMTECH was officially included in the Hong Kong Stock Connect list of eligible securities. The board anticipates that this inclusion will help broaden the company's shareholder base and enhance the trading liquidity of its H-shares. A recent research report from Huaxin Securities noted that the company continues to focus on innovation, with its new PAH treatment drug expected to file an IND application within the year. Considering the sequential clinical application submissions of the company's globally patented innovative drugs, Huaxin Securities has assigned a \"Buy\" investment rating.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CF PHARMTECH (02652) Surges Over 21% in Intraday Trading as Advanced Respiratory Pipeline Accelerates Towards Harvest Phase</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCF PHARMTECH (02652) Surges Over 21% in Intraday Trading as Advanced Respiratory Pipeline Accelerates Towards Harvest Phase\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-18 10:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CF PHARMTECH (02652) saw its shares rise more than 21% during the morning session. At the time of writing, the stock was up 14.54%, trading at HK$28.2, with a turnover of HK$81.96 million. The surge follows recent news that the company's self-developed inhaled powder ICF001, a改良型新药 (chemical drug category 2.1改良型新药) for treating pulmonary arterial hypertension (PAH) and interstitial lung disease-associated pulmonary arterial hypertension (PH-ILD), has had its Investigational New Drug (IND) application formally accepted by China's National Medical Products Administration (NMPA). This marks the company's second吸入制剂改良型创新药 to receive acceptance, following ICF004, signaling that its innovative pipeline in advanced respiratory formulations is accelerating into a harvest period. Starting March 9, CF PHARMTECH was officially included in the Hong Kong Stock Connect list of eligible securities. The board anticipates that this inclusion will help broaden the company's shareholder base and enhance the trading liquidity of its H-shares. A recent research report from Huaxin Securities noted that the company continues to focus on innovation, with its new PAH treatment drug expected to file an IND application within the year. Considering the sequential clinical application submissions of the company's globally patented innovative drugs, Huaxin Securities has assigned a \"Buy\" investment rating.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"","article_id":"1105666137","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1105666137","pubTimestamp":1773800059,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CF PHARMTECH (02652) saw its shares rise more than 21% during the morning session. At the time of writing, the stock was up 14.54%, trading at HK$28.2, with a turnover of HK$81.96 million. The surge...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","02652":"长风药业","VXUS":"国际股票ETF-Vanguard","BK4585":"ETF&股票定投概念","BK1191":"制药"},"translate_title":"随着先进呼吸管道加速进入收获阶段，CF PHARMTECH(02652)盘中交易飙升超过21%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VXUS":1,"02652":1},"content_text":"CF PHARMTECH (02652) saw its shares rise more than 21% during the morning session. At the time of writing, the stock was up 14.54%, trading at HK$28.2, with a turnover of HK$81.96 million. The surge follows recent news that the company's self-developed inhaled powder ICF001, a改良型新药 (chemical drug category 2.1改良型新药) for treating pulmonary arterial hypertension (PAH) and interstitial lung disease-associated pulmonary arterial hypertension (PH-ILD), has had its Investigational New Drug (IND) application formally accepted by China's National Medical Products Administration (NMPA). This marks the company's second吸入制剂改良型创新药 to receive acceptance, following ICF004, signaling that its innovative pipeline in advanced respiratory formulations is accelerating into a harvest period. Starting March 9, CF PHARMTECH was officially included in the Hong Kong Stock Connect list of eligible securities. The board anticipates that this inclusion will help broaden the company's shareholder base and enhance the trading liquidity of its H-shares. A recent research report from Huaxin Securities noted that the company continues to focus on innovation, with its new PAH treatment drug expected to file an IND application within the year. Considering the sequential clinical application submissions of the company's globally patented innovative drugs, Huaxin Securities has assigned a \"Buy\" investment rating.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1105666137","isCrawlerRequest":true}